Lyterian Therapeutics is a biotechnology company focused on developing small molecule therapies for Alzheimer's disease and other age-related disorders. The company targets protein homeostasis and cellular clearance mechanisms that become dysregulated with aging and contribute to neurodegenerative pathology[1].
The company's approach centers on enhancing the cell's natural ability to clear misfolded proteins—including amyloid-beta, tau, and alpha-synuclein—through modulation of autophagy and related protein clearance pathways. This mechanism-based strategy addresses the root cause of protein aggregation rather than just symptom management.
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| LT-001 | Protein homeostasis modulator | Alzheimer's Disease | Preclinical | IND-enabling |
| LT-002 | Autophagy enhancer | Parkinson's Disease | Preclinical | Research |
LT-001 is Lyterian's lead clinical candidate for Alzheimer's disease. This small molecule modulator targets protein homeostasis pathways to enhance clearance of misfolded proteins:
LT-002 is a preclinical candidate targeting Parkinson's disease:
Lyterian develops small molecules that modulate protein homeostasis pathways, including:
Autophagy (self-eating) is a cellular process that degrades and recycles damaged proteins and organelles. In neurodegenerative diseases, autophagy becomes impaired, leading to accumulation of toxic protein aggregates. Lyterian's small molecules aim to restore autophagic flux[2]:
The ubiquitin-proteasome system is another critical pathway for protein clearance. Lyterian's platform includes modulators that:
Compared to antibody-based therapies or gene therapy, small molecule modulators offer:
Lyterian's scientific advisory board includes experts in autophagy, protein aggregation, and neurodegenerative disease research from leading academic institutions.
Lyterian competes with other companies developing autophagy-enhancing approaches: